d'Entremont Tracy S, Sun Weijing
Department of Medicine, Division of Hematology and Oncology, University of Pennsylvanio Medical Center, Philadelphia, Pennsylvania USA.
Cancer Biol Ther. 2003 Jan-Feb;2(1):6-13. doi: 10.4161/cbt.178.
Colorectal cancer is the second most common cause of cancer-related mortality in the United States. The American Cancer Society projects that there will be 107,300 new diagnoses of colorectal cancer in the United States in 2002, and 48,100 deaths will be attributed to colorectal cancer.(1) Although for decades there was only one chemotherapeutic agent with any meaningful activity in colorectal cancer, significant research in the last five years has identified several additional active agents. This review will focus on the recently approved chemotherapeutic combinations including capecitabine, irinotecan and oxaliplatin. We will also discuss preliminary data of molecular targeted therapies and highlight ongoing studies that will likely change the treatment paradigm for colorectal cancer in the future.
在美国，结直肠癌是癌症相关死亡的第二大常见原因。美国癌症协会预计，2002年美国将有107,300例新诊断的结直肠癌病例，48,100例死亡将归因于结直肠癌。（1）尽管几十年来在结直肠癌治疗中只有一种具有任何显著活性的化疗药物，但过去五年的大量研究已发现了几种其他活性药物。本综述将聚焦于最近获批的化疗联合方案，包括卡培他滨、伊立替康和奥沙利铂。我们还将讨论分子靶向治疗的初步数据，并重点介绍可能在未来改变结直肠癌治疗模式的正在进行的研究。
